SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer

Bin Li, Ranran Pan, Cong Zhou, Jie Dai, Yiyi Mao, Min Chen, Tianyi Huang, Xiuru Ying, Haochang Hu, Jun Zhao, Wei Zhang, Shiwei Duan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Aim:SMYD3 encodes histone lysine methyltransferase. The goal of our study was to investigate the association between SMYD3 methylation and colorectal cancer (CRC). Materials & methods: SMYD3 methylation was measured by quantitative methylation-specific PCR method in 117 pairs of CRC tumor and para-tumor tissues. Results: Significantly lower SMYD3 methylation was observed in CRC tumor tissues than para-tumor tissues (p = 0.002). Further subgroup analysis by clinical features showed that significantly lower SMYD3 methylation were only observed in the CRC patients with tumors of moderately and well differentiation, positive lymph node metastasis, and stage III + IV. Conclusion: Our work reported for the first time that SMYD3 promoter hypomethylation was associated with CRC.

Original languageEnglish (US)
Pages (from-to)1825-1834
Number of pages10
JournalFuture Oncology
Issue number18
StatePublished - Aug 2018


  • DNA methylation
  • SMYD3
  • colorectal cancer
  • promoter
  • quantitative methylation-specific PCR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'SMYD3 promoter hypomethylation is associated with the risk of colorectal cancer'. Together they form a unique fingerprint.

Cite this